Modern says that more than 40% of participants have enrolled for the COVID-19 vaccine trial

FILE PHOTO: A sign marks the headquarters of Modern Therapeutics, a Cambridge, Massachusetts, US, developing a vaccine against coronavirus disease (COVID-19) on May 18, 2020. REUTERS (Brian Snyder)

(Reuters) – Drug developer Modern Inc. (MRNA.O) Said on Friday that it has so far tested its COVID-19 vaccine candidate in a 30,000-volunteer American trial in the final phase nominating 13,194 participants.

In a tweet, the company also stated that 18% of the currently enrolled participants are of Black, Latino, American Indian or Alaskan origin, most affected by the epidemic of coronovirus virus.

Modern began studying its vaccine candidate mRNA-1273 in July and hopes to complete enrollment in September. The US trial of 30,000 subjects is one of the first late-stage studies conducted by the Trump administration to accelerate the development of measures against novel coronoviruses, hoping that an effective vaccine would help end the epidemic.

Last week, the company entered into a supply agreement with the US government to deliver 100 million doses of its potential COVID-19 vaccine for about $ 1.5 billion.

Modern, which has never brought a vaccine to market, previously received nearly $ 1 billion from the US government, which is helping to bankroll several vaccine candidates under its Operation Tana Momentum program.

Black and Latino Americans are infected with COVID-19 at more than double the rate of white Americans, with Native Americans also infecting at higher rates, research has shown. Groups have historically been presented in clinical trials.

A top executive of Pfizer (PFE.N) Told Reuters that about 19% of the 11,000 people so far registered in the 30,000-volunteer US trial of their COVID-19 vaccine with German partner BioNotech (22UAy.F) Are black or latino.

Reporting of Mrinalika Roy in Bengaluru; Editing by Sonya Hepinstall

Our standard:Thomson Reuters Trust Theory.

Leave a Reply

Your email address will not be published.